tradingkey.logo
tradingkey.logo
Suchen

Biontech SE

BNTX
Zur Watchlist hinzufügen
91.220USD
+1.220+1.36%
Handelsschluss 06/26, 16:00ETKurse um 15 Minuten verzögert
23.07BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Biontech SE Unternehmen

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SE Informationen

BörsenkürzelBNTX
Name des UnternehmensBiontech SE
IPO-datumOct 10, 2019
CEOSahin (Ugur)
Anzahl der mitarbeiter6772
WertpapierartDepository Receipt
GeschäftsjahresendeOct 10
AddresseAn der Goldgrube 12
StadtMAINZ
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl55131
Telefon4949613190840
Websitehttps://www.biontech.com/
BörsenkürzelBNTX
IPO-datumOct 10, 2019
CEOSahin (Ugur)

Führungskräfte von Biontech SE

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Biontech SE?

Die fünf größten Anteilseigner von Biontech SE sind: Dr. Sierk Poetting, Ph.D.

Wie viele Institutionen halten Anteile an Biontech SE (BNTX)?

Mit Stand vom 2026Q1 halten 802 Institutionen Anteile an Biontech SE, mit einem Gesamtmarktwert von etwa 51.86M, was 20.51% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1292358.00 gestiegen.

Was ist die größte Einnahmequelle von Biontech SE?

Am 2026Q1 erzielte das Geschäft mit Collaboration Revenue für Biontech SE den höchsten Umsatz in Höhe von 84.43M, was 77.75% des Gesamtumsatzes entspricht.
KeyAI